Zobrazeno 1 - 10
of 96
pro vyhledávání: '"du Bois, A"'
Autor:
Enrico Vizza, Sonia Magni, Beyhan Ataseven, Vito Chiantera, Nicolò Bizzarri, Philipp Harter, Daniela Giuliani, Anna Fagotti, Debora Ferrari, Anna Myriam Perrone, Pierandrea De Iaco, Francesca De Felice, Jvan Casarin, Andreas du Bois, Robert Fruscio, Giacomo Corrado, Mareike Bommert, Giovanni Scambia, Stefano Cianci
Objective: The therapeutic role of pelvic and para-aortic lymphadenectomy in surgical staging of apparent early-stage epithelial ovarian cancer (eEOC) is still under debate. The aim of this study was to evaluate the potential therapeutic role of syst
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20118a1f853b9e3f6845eb7d6ef4fd46
http://hdl.handle.net/11585/810972
http://hdl.handle.net/11585/810972
Autor:
Jalid Sehouli, Martina Gropp-Meier, Behnaz Aminossadati, Nikolaus de Gregorio, Alexander Burges, Ulrich Canzler, Ahmed El-Balat, Barbara Schmalfeldt, Annette Hasenburg, Pauline Wimberger, Christian Jackisch, Uwe Wagner, Philipp Harter, Petra Neuser, Hans-Joachim Lück, Andreas du Bois, Werner Meier, Sven Mahner, Jacobus Pfisterer, Stefan Kommoss
Publikováno v:
Archives of Gynecology and Obstetrics. 301:1267-1274
Although thrombocytosis in patients with primary ovarian cancer has been widely investigated, there are only very few data about the role of thrombocytosis in recurrent ovarian cancer. The aim of our study was to investigate the impact of pretreatmen
Publikováno v:
Journal of Clinical Oncology. 37:2398-2405
Autor:
Felix Hilpert, Andreas du Bois
Publikováno v:
Expert Review of Anticancer Therapy. 18:3-7
Patient-reported outcomes (PROs), including quality-of-life considerations, are increasingly becoming key factors in clinical decision making. Areas covered: This review provides an overview of the current status of PROs in guiding clinical trial des
Autor:
Olli Carpén, Andreas du Bois, Elena Ioana Braicu, Hagen Kulbe, Johanna Hynninen, Philipp Harter, Mika Hilvo, Jalid Sehouli, Antti Jylhä, Sinikka Oksa, Mitja Lääperi, Sven Mahner, Sakari Hietanen, Kaisa Huhtinen, Liina Salminen
Publikováno v:
Cancers
Volume 13
Issue 8
Salminen, L, Braicu, E I, Lääperi, M, Jylhä, A, Oksa, S, Hietanen, S, Sehouli, J, Kulbe, H, Bois, A D, Mahner, S, Harter, P, Carpén, O, Huhtinen, K, Hynninen, J & Hilvo, M 2021, ' A novel two-lipid signature is a strong and independent prognostic factor in ovarian cancer ', Cancers, vol. 13, no. 8, 1764 . https://doi.org/10.3390/cancers13081764
Cancers, Vol 13, Iss 1764, p 1764 (2021)
Volume 13
Issue 8
Salminen, L, Braicu, E I, Lääperi, M, Jylhä, A, Oksa, S, Hietanen, S, Sehouli, J, Kulbe, H, Bois, A D, Mahner, S, Harter, P, Carpén, O, Huhtinen, K, Hynninen, J & Hilvo, M 2021, ' A novel two-lipid signature is a strong and independent prognostic factor in ovarian cancer ', Cancers, vol. 13, no. 8, 1764 . https://doi.org/10.3390/cancers13081764
Cancers, Vol 13, Iss 1764, p 1764 (2021)
Simple Summary Most ovarian cancer patients initially show a response to primary treatments, but the development of refractory disease is a major problem. Currently, there are no blood-based prognostic biomarkers, and the prognosis of a patient is de
Autor:
Hans-Peter Sinn, Ali Bashashati, Anna V. Tinker, Hans W. Nijman, Andreas D. Hartkopf, Felix K. F. Kommoss, Florian Heitz, Michael S. Anglesio, Derek S. Chiu, Lukas Feil, Emily F Thompson, Friedrich Kommoss, Mary Anne Brett, Martin Köbel, P Krämer, Aline Talhouk, Katherine Dixon, Bernhard K. Krämer, Sara Y. Brucker, Annette Staebler, Marco de Bruyn, Janine Senz, David Farnell, Naveena Singh, Philipp Harter, Zhouchunyang Xia, Daniëlla A Scheunhage, Tayyebeh M. Nazeran, Rory F L Hammond, M Grube, J Pasternak, H.-W. Vollert, Cornelis D. de Kroon, Sabine Heublein, Jessica N. McAlpine, Stefan Kommoss, Samuel Leung, Tjalling Bosse, Andreas du Bois, Ranjit Manchanda, Evan S. Cairns
Publikováno v:
Clinical Cancer Research, 26(20), 5400-5410. AMER ASSOC CANCER RESEARCH
Purpose: Endometrioid ovarian carcinoma (ENOC) is generally associated with a more favorable prognosis compared with other ovarian carcinomas. Nonetheless, current patient treatment continues to follow a “one-size-fits-all” approach. Even though
Autor:
Martin K. Walz, Pier Francesco Alesina, Florian Heitz, Stephanie Schneider, Teresa González Luengo, Kai-Uwe Waltering, Sebastian Heikaus, Beyhan Ataseven, Sonia Prader, Philipp Harter, Violeta Brunkhorst, Beate Meier, Andreas du Bois, Jens-Albrecht Koch, Pauly Nina, Alexander Traut, Harald-Thomas Groeben
Publikováno v:
Annals of Surgical Oncology. 25:3372-3379
Sarcopenia was reported as a prognostic factor in cancer patients. Using computed tomography (CT), we analyzed the impact of sarcopenia on overall survival (OS) in patients with advanced epithelial ovarian cancer (EOC) after primary debulking surgery
Autor:
Florian Heitz, Alexander Traut, Harald-Thomas Groeben, Pier Francesco Alesina, Beyhan Ataseven, Annettte Brueckner, Violeta Brunkhorst, Stephanie Schneider, Sebastian Heikaus, Martin K. Walz, Annett Kahl, Philipp Harter, Sonia Prader, Andreas du Bois, Beate Meier
Publikováno v:
Annals of Surgical Oncology. 24:3692-3699
We evaluated the prognostic impact of the age-adjusted Charlson Comorbidity Index (ACCI) on both postoperative morbidity and overall survival (OS) in patients with advanced epithelial ovarian cancer (EOC) treated at a tertiary gynecologic cancer cent
Autor:
Christian Kurzeder, Andreas du Bois, Philipp Harter, Annett Kahl, Alexander Traut, Sonia Prader, Martin K. Walz, Jakob Hinrichs, Stephanie Schneider, Beyhan Ataseven, Harald Groeben, Violetta Brunkhorst, Christoph Grimm, Florian Heitz, Beate Meier, Pier Francesco Alesina
Publikováno v:
Gynecologic Oncology. 146:498-503
Objective To identify risk factors for anastomotic leakage (AL) in patients undergoing primary advanced ovarian cancer surgery and to evaluate the prognostic implication of AL on overall survival in these patients. Methods We analyzed our institution
Autor:
Andreas du Bois, Jacobus Pfisterer, Philipp Harter, Sandra Saß, Felix Hilpert, Thorsten Heilmann, Eric Pujade-Lauraine, Antje Marie Hempel, Jürgen Hedderich
Publikováno v:
Gynecologic oncology. 153(3)
Elderly ovarian cancer patients are underrepresented in clinical trials and disadvantaged with regard to therapeutic standards compared to other age groups. We explored the specific performance of a subset of patients aged ≥70 years in a large meta